America is on the brink of a new golden age of medicine. But can we afford it?

The U.S. leads the world in medical innovation, producing new treatments that improve and extend the lives of millions of patients. Our most recent triumph: gene therapies and other curative technologies that make it easier to deliver cures for some of the most serious diseases. At the same time, however, the rise of high-deductible health plans has shifted a greater share of prescription costs onto patients, potentially putting some therapies out of reach. The question now is not whether an era of precision medicine is at hand, but whether we can afford it.

As Senior Vice President of Eli Lily and Company, Christi Shaw oversees the development of new therapies to treat Alzheimer's and cardiovascular diseases. In 2016, Shaw resigned as president of Novartis to become the full-time caretaker of her sister, who was battling multiple myeloma. Shaw will be joined by Dr. Tom Coburn—MI Senior Fellow, physician, former U.S. Senator, and three-time cancer survivor—and Dan Goldberg, Senior Health Reporter at Politico.

212-599-7000
communications@manhattan-institute.org